论文部分内容阅读
目的:比较克拉霉素与阿奇霉素治疗小儿支原体肺炎的疗效与安全性。方法:将100例支原体肺炎患儿随机分为研究组和对照组各50例,研究组予克拉霉素分散片15 mg/(kg.d)连服5 d停2 d,对照组予阿奇霉素分散片10 mg/(kg.d)连服3 d停4 d,为1个疗程,未痊愈者追加1个疗程,对两组临床疗效和不良反应进行观察比较。结果:在干预后第1周末和第2周末,研究组疗效均与对照组相当(Z=-0.161和-0.489,P均>0.05);两组干预后症状体征评分均低于干预前(F组内=757.020,P=0.000),干预与时间存在交互效应(F交互=2.294,P=0.044),但无组间差别(F组间=0.301,P=0.584);在干预后第5天,研究组减分幅度大于对照组(t=2.300,P<0.05),其余各时点两组间比较差异无统计学意义(t=1.578、0.157、0.739和0.341,P>0.05)。两组间不良反应比较差异无统计学意义(χ2=0.208,P=0.648)。结论:克拉霉素治疗小儿支原体肺炎疗效确切,与阿奇霉素相当,且起效较快,安全性好。
Objective: To compare the efficacy and safety of clarithromycin and azithromycin in the treatment of children with mycoplasma pneumonia. Methods: 100 cases of children with mycoplasma pneumonia were randomly divided into study group and control group, 50 cases in each group. The study group was treated with clarithromycin dispersible tablets 15 mg / (kg.d) even for 5 days for 2 days. The control group was given azithromycin Tablets 10 mg / (kg.d) even for 3 d stop 4 d, a course of treatment, who did not heal additional 1 course of treatment were observed and compared the clinical efficacy and adverse reactions. Results: The efficacy of the study group was similar to that of the control group (Z = -0.161 and -0.489, both P <0.05) at the first weekend and the second weekend after intervention. Symptoms and signs of the two groups after intervention were lower than those before the intervention (F = 2.94, P = 0.044), but no difference between groups (F = 0.301, P = 0.584); on the 5th day after the intervention (T = 2.300, P <0.05). There was no significant difference between the two groups at other time points (t = 1.578,0.157,0.739 and 0.341, P> 0.05). There was no significant difference in adverse reactions between the two groups (χ2 = 0.208, P = 0.648). Conclusion: Clarithromycin treatment of children with mycoplasma pneumonia curative effect is exact, and azithromycin, and rapid onset, good safety.